- Home
- GGRP vs IMNN Comparison
GGRP vs IMNN Comparison
Compare GGRP & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.64
HOLD
Current Price
$2.99
Company Overview
Basic Information| Metric | GGRP | IMNN |
|---|---|---|
| Founded | 2016 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 11.0M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GGRP | IMNN |
|---|---|---|
| Price | $0.64 | $2.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 61.8K | 17.5K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.37 |
| 52 Week High | $0.65 | $9.32 |
Technical Indicators
Market Signals| Indicator | GGRP | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 43.18 |
| Support Level | $0.55 | $3.03 |
| Resistance Level | $0.64 | $3.16 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 73.11 | 23.73 |
Price Performance
Historical Comparison GGRP
IMNN
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).